Business Context and Reporting Period
Company: Cognition Therapeutics, Inc. (CGTX)
Filing Type: Form 8-K (Current Report)
Date of Report: June 24, 2026
Reporting Period: Specific event date (June 24, 2026)
Business Context: The Company is an emerging growth company incorporated in Delaware. This filing reports the receipt of written feedback from the U.S. Food and Drug Administration (FDA) following a meeting held in May 2026.
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the receipt of written feedback from the FDA regarding the Company's recent May 2026 meeting. No financial or operational changes compared to a prior period are detailed in this document.
Guidance, Outlook, and Risks
Management Commentary: The Company issued a press release (Exhibit 99.1) detailing the FDA feedback. The filing itself does not contain specific text regarding future guidance, outlook, or detailed risk factors beyond the context of the regulatory interaction.
Unusual Items: None reported in this filing.
Investor Verification Checklist
- Review the full text of the Press Release (Exhibit 99.1) to understand the specific nature of the FDA feedback.
- Verify the impact of the FDA feedback on the Company's drug development timeline and regulatory strategy.
- Check subsequent filings for any updates on the Company's cash position, as this 8-K does not disclose liquidity metrics.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.